Sugar 1week post stem cell therapy

By: Tim O #39;Neill, DVM

See more here:
Sugar 1week post stem cell therapy - Video

Stem Cell Therapy- Victoria Hicks

By: Victoria Hicks

View post:
Stem Cell Therapy- Victoria Hicks - Video

BBC iScience Stem Cell Therapy
A fun, engaging and relevant programme, inspiring the viewer to consider the science within and how scientific process can be used to test ideas and develop theories, rather than just looking...

By: Lammas Science

Link:
BBC iScience Stem Cell Therapy - Video

VetRegen stem cell therapy.
Please watch this Video though in Polish most is visual. I took out the longer news cast that was Filmed Live in Warsaw My wife Joanna was asked too be on a ...

By: stephen sanford

Original post:
VetRegen stem cell therapy. - Video

May 27 2013

Five stroke victims have shown small signs of recovery following pioneering stem cell therapy.

Prof Keith Muir, of Glasgow University, said the results were "not what we would have expected" from the group of patients who had previously shown no indications of their conditions improving.

The trial involved injecting stem cells directly into the damaged parts of the patients' brains, with the hope that they would turn into healthy tissue or "kick-start" the body's own repair processes.

Frank Marsh, 80, one of the nine patients taking part in the trial at Glasgow's Southern General Hospital, told the BBC he had seen improvements in the use of his left hand.

"I can grip certain things that I never gripped before, like the hand rail at the baths, with my left hand as well as my right," he said."It still feels fairly weak and it's still a wee bit difficult to co-ordinate, but it's much better than it was." He added: "I'd like to get back to playing my piano."

His wife Claire said: "He had reached a plateau and wasn't really improving (after his stroke). But following the operation he is able to do things he couldn't do before, such as make coffee, dressing and holding on to things."

The study involved patients who suffered strokes some time ago and had shown no signs of making any further spontaneous improvement.

Prof Muir said the results were "at the present time not what we would have expected in this group but far from being able to say whether it's something specifically related to the cells".

He told BBC Radio 4's Today programme: "We know that some of the cells will survive and potentially turn into relevant tissue. We also suspect that a large part of what we do is kick-starting repair processes that are already present in the body. So there's probably a mixture of things going on. Quite what it is that's happening in the patients, we won't know for some time to come."

Continued here:
UK & World News: Stem cell therapy 'shows results'

Kilian Before After Stemlogix Stem Cell Therapy

By: Jim Cain

Here is the original post:
Kilian Before

ANCFuturePerfect-The Medical City Stem Cell Therapy

By: Chelle De Vera

Here is the original post:
ANCFuturePerfect-The Medical City Stem Cell Therapy - Video

NEW YORK, April 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

http://www.reportlinker.com/p01075729/Stem-Cell-Therapy-Market-in-Asia-Pacific-to-2018---Commercialization-Supported-by-Favorable-Government-Policies-Strong-Pipeline-and-Increased-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity". The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals' JR-031 (2014) in Japan and FCB Pharmicell's Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Scope

- Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore - In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. - Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. - Key drivers and restraints that have a significant impact on the market. - Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost - Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.

View post:
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies ...

Public release date: 22-Apr-2013 [ | E-mail | Share ]

Contact: Mika Ono mikaono@scripps.edu 858-784-2052 Scripps Research Institute

LA JOLLA, CA April 22, 2013 In a serendipitous discovery, scientists at The Scripps Research Institute (TSRI) have found a way to turn bone marrow stem cells directly into brain cells.

Current techniques for turning patients' marrow cells into cells of some other desired type are relatively cumbersome, risky and effectively confined to the lab dish. The new finding points to the possibility of simpler and safer techniques. Cell therapies derived from patients' own cells are widely expected to be useful in treating spinal cord injuries, strokes and other conditions throughout the body, with little or no risk of immune rejection.

"These results highlight the potential of antibodies as versatile manipulators of cellular functions," said Richard A. Lerner, the Lita Annenberg Hazen Professor of Immunochemistry and institute professor in the Department of Cell and Molecular Biology at TSRI, and principal investigator for the new study. "This is a far cry from the way antibodies used to be thought ofas molecules that were selected simply for binding and not function."

The researchers discovered the method, reported in the online Early Edition of the Proceedings of the National Academy of Sciences the week of April 22, 2013, while looking for lab-grown antibodies that can activate a growth-stimulating receptor on marrow cells. One antibody turned out to activate the receptor in a way that induces marrow stem cellswhich normally develop into white blood cellsto become neural progenitor cells, a type of almost-mature brain cell.

Nature's Toolkit

Natural antibodies are large, Y-shaped proteins produced by immune cells. Collectively, they are diverse enough to recognize about 100 billion distinct shapes on viruses, bacteria and other targets. Since the 1980s, molecular biologists have known how to produce antibodies in cell cultures in the laboratory. That has allowed them to start using this vast, target-gripping toolkit to make scientific probes, as well as diagnostics and therapies for cancer, arthritis, transplant rejection, viral infections and other diseases.

In the late 1980s, Lerner and his TSRI colleagues helped invent the first techniques for generating large "libraries" of distinct antibodies and swiftly determining which of these could bind to a desired target. The anti-inflammatory antibody Humira, now one of the world's top-selling drugs, was discovered with the benefit of this technology.

Last year, in a study spearheaded by TSRI Research Associate Hongkai Zhang, Lerner's laboratory devised a new antibody-discovery techniquein which antibodies are produced in mammalian cells along with receptors or other target molecules of interest. The technique enables researchers to determine rapidly not just which antibodies in a library bind to a given receptor, for example, but also which ones activate the receptor and thereby alter cell function.

Continue reading here:
Scientists find antibody that transforms bone marrow stem cells directly into brain cells

Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1) Patient had a fall on 31st December 2012 due to whi...

By: neurogenbsi

Go here to read the rest:
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. - Video

Editor's Choice Academic Journal Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Stem Cell Research Article Date: 21 Mar 2013 - 12:00 PDT

Current ratings for: Cell Therapy Shows Promise For Advanced Leukemia In Adults

3 (1 votes)

1 (1 votes)

Similar immune-system therapy has proven effective in children with this cancer as well as in adults with a similar type of leukemia, however, this is the first time this specific therapy has worked in adults.

The findings of the current study were based on five patients with acute lymphoblastic leukemia (ALL). T cells were extracted from the patient and modified to express a receptor for protein on other immune cells - called B cells - that are found in both cancerous and healthy tissues.

ALL is a cancer of the blood and bone marrow which progresses quickly - if left untreated, patients sometimes die within weeks. The first treatment is generally three phases of chemotherapy drugs.

For most patients, this puts the cancer in remission. However, it often comes back. The second treatment agenda is usually another round of chemotherapy followed by a bone marrow transplant.

The authors point out that when the cancer returns, it is often immune to many chemotherapy drugs. Therefore, Dr. Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City, and his colleagues set out to test a different approach.

The five participating patients received infusions of their altered T cells after undergoing standard chemotherapy. All five patients saw a total remission - for one patient this occured within just eight days, according to the researchers.

Go here to see the original:
Cell Therapy Shows Promise For Advanced Leukemia In Adults

Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy Before and After
Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy Before and After After Stem Cell Therapy 1 Stamina has increased Exercise tolerance has improved 2 She can lift her leg more up while in standing 3 Hip flexion is easier and range has improved 4 Bending hip and knee in supine is easier 5 She can bring her leg forward in knee standing without support 6 Can now bring the knees to her chest 7 SLR range has improved Stem Cell Therapy done at Dr Alok Sharma neurogen Brain and ...

By: neurogenbsi

Read the original:
Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy Before and After - Video

Dr Alok Sharma Stem Cell Therapy for Duchenne Muscular Dystrophy in Gujarati
Dr Alok Sharma Stem Cell Therapy for Duchenne Muscular Dystrophy in Gujarati 16 years old male with history of frequent falls and being slow as compared to p...

By: neurogenbsi

See the article here:
Dr Alok Sharma Stem Cell Therapy for Duchenne Muscular Dystrophy in Gujarati - Video

Stem Cell Therapy for Autism Part 2
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy Psychology assessment: 1) Now his duration of expressing his anger has reduced (ie) previously he would get angry and it would continue for half an hour to 20 minutes. Now it has reduced to 10 minutes. 2) Now his level of understanding and tolerance level has increased (ie) before he would get upset even before his parents spoke whereas now he listens to them and follows commands. 3) Now he has started writing (ie) now he can copy from the book and he can do so for a duration of ½ hour to 1 hour which wasn #39;t possible at all before. 4) Previously he had obsessive features like washing his hands repetitively but now it has reduced. 5) Previously he would disturb others in the classroom by shouting or sitting next to them but now he doesn #39;t disturb others ...

By: neurogenbsi

See the article here:
Stem Cell Therapy for Autism Part 2 - Video

Stem Cell Therapy for Autism Part 1 Tamil
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy 1. Angry spells are short lasting than before. Earlier, if he used to be upset for half hour at a stretch, now he calms down in 2 minutes. 2. Did not ask for toothpaste for second time which he used to do daily. 3. He does not insist on bathing 2-3 times a day like before. Now, he takes bath once a day. 4. Visits washroom once in 2-3 hours and then washes his hand normally and leaves the washroom. Earlier, he used to go to washroom every hourly and wash his hand, spill water on his clothes and arms. 5. Eye contact attention span improved. 6. Sitting tolerance improved and attends for 30 mins session. 7. Listening skills and observation skills on demand improved. 8. Screaming behavior reduces when given paper tearing activity. 9. His parents feel his ...

By: neurogenbsi

See the article here:
Stem Cell Therapy for Autism Part 1 Tamil - Video

Public release date: 28-Feb-2013 [ | E-mail | Share ]

Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center

WINSTON-SALEM, N.C. Feb. 28, 2013 Researchers at Wake Forest Baptist Medical Center and colleagues have identified a special population of adult stem cells in bone marrow that have the natural ability to migrate to the intestine and produce intestinal cells, suggesting their potential to restore healthy tissue in patients with inflammatory bowel disease (IBD).

Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions ulcerative colitis and Crohn's disease in which the intestines become red and swollen and develop ulcers, probably as the result of the body having an immune response to its own tissue.

While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. Because these therapies aren't always effective, scientists hope to use stem cells to develop an injectable cell therapy to treat IBD.

The research findings are reported online in the FASEB Journal (the journal of the Federation of American Societies for Experimental Biology) by senior researcher Graca Almeida-Porada, M.D., Ph.D., professor of regenerative medicine at Wake Forest Baptist's Institute for Regenerative Medicine, and colleagues.

The new research complements a 2012 report by Almeida-Porada's team that identified stem cells in cord blood that are involved in blood vessel formation and also have the ability to migrate to the intestine.

"We've identified two populations of human cells that migrate to the intestine one involved in blood vessel formation and the other that can replenish intestinal cells and modulates inflammation," said Almeida-Porada. "Our hope is that a mixture of these cells could be used as an injectable therapy to treat IBD."

The cells would theoretically induce tissue recovery by contributing to a pool of cells within the intestine. The lining of the intestine has one of the highest cellular turnover rates in the body, with all cell types being renewed weekly from this pool of cells, located in an area of the intestine known as the crypt.

In the current study, the team used cell markers to identify a population of stem cells in human bone marrow with the highest potential to migrate to the intestine and thrive. The cells express high levels of a receptor (ephrin type B) that is involved in tissue repair and wound closure.

See the article here:
Research supports promise of cell therapy for bowel disease

Stem Cell Therapy Bio1103 Group 29 AM
Peyton Manning and Stem Cell Research

By: megmitchell93

See original here:
Stem Cell Therapy Bio1103 Group 29 AM - Video

Age-Related Macular Degeneration and Retinal Stem Cell Therapy
The problems of AMD and its potential treatment with Retinal Stem Cell Therapy BIO 1103 at UGA

By: grayson3447

Continue reading here:
Age-Related Macular Degeneration and Retinal Stem Cell Therapy - Video

Feb. 21, 2013 Cell therapy is a promising alternative to tissue and organ transplantation for diseases that are caused by death or poor functioning of cells. Considering the ethical discussions surrounding human embryonic stem cells, a lot is expected of the so-called 'induced pluripotent stem cells' (iPS cells). However, before this technique can be applied effectively, a lot of research is required into the safety and efficacy of such iPS cells. VIB scientists associated to the UGent have developed a mouse model that can advance this research to the next step.

Lieven Haenebalcke (VIB/UGent): "iPS cells have enormous therapeutic potential, but require more thorough testing before they can be used for such purposes. Using our new mouse model, we can study which mechanisms determine the identity of a cell. This knowledge is essential before we can use cell therapy for regenerative medicine."

Jody Haigh (VIB/UGent): "If we want to give cell therapy a future, then we must continue this type of research and invest in the further development of such technologies. This will result in an improved insight into cellular identity and -- in the long term -- safer options of applying iPS cells or cells derived from iPS cells in clinical studies."

Cell therapy -- replacing cells to provide a cure

Cell therapy is the replacement of lost or poorly functioning cells in patients. For example, such cell therapies could be used to repair the heart muscle after a heart attack, joints affected by arthritis, the pancreas in diabetes or the spine in certain forms of paralysis. This requires cells that are able to multiply in the laboratory and that can be converted to healthy cells of the desired cell type. Human embryonic stem cells meet these criteria, but they are ethically controversial.

iPS cells -- a promising alternative to embryonic stem cells

Shinya Yamanaka recently developed a fairly simple method to reprogram differentiated cells -- such as skin cells -- back to stem cells, so-called "induced pluripotent stem cells" (iPS cells). This earned him the Nobel Prize for Medicine in 2012 (shared with John Gurdon). These iPS cells can be generated using only 4 "reprogramming factors."

As is the case with embryonic stem cells, these iPS cells can be used to produce other cell types, such as heart muscle cells or nerve cells. They can also be cultured indefinitely and there are no ethical objections as they are not obtained from human embryos left over after IVF, but from adult individuals. Furthermore, iPS cells are obtained from the patient and this reduces the risk of rejection during therapeutic applications.

Essential research possible

Before iPS cells can be used effectively and safely as a therapy, it is essential that we gain clear insight into which molecular mechanisms determine the identity of a cell; why and how a cell develops into -- for example -- a heart muscle cell, a nerve cell or a blood cell. In order to do so, Lieven Haenebalcke and Jody Haigh have developed a mouse model that will enable them to conduct this research. They succeeded in creating iPS cells from a variety of mouse cells. Furthermore, the new model allows the investigators to replace the 4 reprogramming factors in these iPS cells efficiently with specific genes in order to create targeted different cell types, such as functional heart muscle cells.

The rest is here:
Cell therapy: New mouse model promises to advance research on induced pluripotent stem cells

Stem Cell Therapy - Ehrlich Animal Hospital #39;s Arthritis Therapy Center
Ehrlich Animal Hospital offers several degrees of specialty arthritis therapies and treatments that may not be currently available at other local animal hospitals. Our hospital is unique in that we offer cutting edge arthritis therapy technologies: therapeutic laser treatments, injectable medications and oral medications to reduce inflammation and discomfort.

By: EhrlichAnimalHospita

Read more:
Stem Cell Therapy - Ehrlich Animal Hospital's Arthritis Therapy Center - Video